Report cover image

Leukemia Therapeutics Market by Type (Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia), Treatment Type (Chemotherapy, Targeted Drugs & Immunotherapy), Molecule Type, Mode of Administration, Gender - Global Forecast 2024-20

Publisher 360iResearch
Published Jan 15, 2024
Length 199 Pages
SKU # IRE18445445

Description

Leukemia Therapeutics Market by Type (Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia), Treatment Type (Chemotherapy, Targeted Drugs & Immunotherapy), Molecule Type, Mode of Administration, Gender - Global Forecast 2024-2030


The Leukemia Therapeutics Market size was estimated at USD 15.64 billion in 2023 and expected to reach USD 16.73 billion in 2024, at a CAGR 7.02% to reach USD 25.17 billion by 2030.

Global Leukemia Therapeutics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Leukemia Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Leukemia Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Leukemia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Biogen Inc, Bristol Myers Squibb Company, Eisai Co., Ltd, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corp, Johnson & Johnson Services, Inc., Merck KGaA, Novartis International AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Leukemia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Acute Lymphocytic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Treatment Type
Chemotherapy

Targeted Drugs & Immunotherapy

Molecule Type
Biologics

Small Molecules

Mode of Administration
Injectable Mode

Oral Mode

Gender
Female

Male

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Leukemia Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Leukemia Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Leukemia Therapeutics Market?
4. What is the market share of the leading vendors in the Leukemia Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Leukemia Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

199 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Leukemia Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of leukemia cases
5.1.1.2. Growing need for cancer therapy
5.1.1.3. Increasing investment in healthcare sector
5.1.2. Restraints
5.1.2.1. High cost of treatment and development of new therapeutics
5.1.3. Opportunities
5.1.3.1. Development of innovative diagnostic and therapeutics for leukemia patients
5.1.3.2. Expanding investments in the healthcare sector and favorable government initiatives
5.1.4. Challenges
5.1.4.1. Stringent regulatory scenario
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Leukemia Therapeutics Market, by Type
6.1. Introduction
6.2. Acute Lymphocytic Leukemia
6.3. Acute Myeloid Leukemia
6.4. Chronic Lymphocytic Leukemia
6.5. Chronic Myeloid Leukemia
7. Leukemia Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3. Targeted Drugs & Immunotherapy
8. Leukemia Therapeutics Market, by Molecule Type
8.1. Introduction
8.2. Biologics
8.3. Small Molecules
9. Leukemia Therapeutics Market, by Mode of Administration
9.1. Introduction
9.2. Injectable Mode
9.3. Oral Mode
10. Leukemia Therapeutics Market, by Gender
10.1. Introduction
10.2. Female
10.3. Male
11. Americas Leukemia Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Leukemia Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.
10. South Korea
12.
11. Taiwan
12.
12. Thailand
12.
13. Vietnam
13. Europe, Middle East & Africa Leukemia Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.
10. Nigeria
13.
11. Norway
13.
12. Poland
13.
13. Qatar
13.
14. Russia
13.
15. Saudi Arabia
13.
16. South Africa
13.
17. Spain
13.
18. Sweden
13.
19. Switzerland
13.
20. Turkey
13.
21. United Arab Emirates
13.
22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. AstraZeneca PLC
15.1.3. Biogen Inc
15.1.4. Bristol Myers Squibb Company
15.1.5. Eisai Co., Ltd
15.1.6. F. Hoffmann-La Roche AG
15.1.7. Gilead Sciences, Inc.
15.1.8. GlaxoSmithKline PLC
15.1.9. Incyte Corp
15.1.
10. Johnson & Johnson Services, Inc.
15.1.
11. Merck KGaA
15.1.
12. Novartis International AG
15.1.
13. Pfizer Inc.
15.1.
14. Sanofi S.A.
15.1.
15. Takeda Pharmaceutical Company Limited
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 1. LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. LEUKEMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LEUKEMIA THERAPEUTICS MARKET DYNAMICS
FIGURE 7. LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 10. LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
FIGURE 12. LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 14. LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2023 VS 2030 (%)
FIGURE 16. LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us